



Clinical trial results: A Study of V114 and Acute Otitis Media in Children (PNEU-ERA) Summary

EudraCT number	2023-001146-11
Trial protocol	Outside EU/EEA
Global end of trial date	22 December 2025

Results information

Result version number	v1 (current)
This version publication date	02 July 2026
First version publication date	02 July 2026

Trial information

Trial identification

Sponsor protocol code	V114-032
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04193215
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 December 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 December 2025
Global end of trial reached?	Yes
Global end of trial date	22 December 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to evaluate V114 in the prevention of vaccine-type acute otitis media (VT-AOM) and the safety of V114 with respect to the proportion of participants with serious adverse events (SAEs) through completion of the study. The primary hypothesis is that V114 is superior to no V114 in preventing VT-AOM as assessed by the incidence of VT-AOM.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 September 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Thailand: 7119
Worldwide total number of subjects	7119
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	7119
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study recruited healthy infants approximately 2 months (42 to 90 days, inclusive) of age, without a history of invasive pneumococcal disease or prior administration of any pneumococcal vaccine.

Pre-assignment

Screening details:

A total of 7119 participants were randomized in a 1:1 ratio to receive either, the 4-dose V114 vaccine regimen (V114), or no V114 vaccine (Control Group), concomitantly alongside other licensed paediatric vaccines.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

Arms

Are arms mutually exclusive?	Yes
Arm title	V114 Group

Arm description:

Participants received a single 0.5 mL intramuscular (IM) injection of V114 administered as a 4dose series on Visits 1,2,3, and 4, at approximately 2,4, 6, and 12 months of age respectively. V114 was administered concomitantly with routine licensed pediatric vaccines: INFANRIX™ hexa and RotaTeq™ on Visits 1, 2, and 3; and M M R™ II and VARIVAX™ (Dose 1) on Visit 4. On Visit 5 (approximately 18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit which and no study vaccines will be administered. For these participants, licensed VAQTA™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and VAQTA™ (Dose 2) was administered in a blinded manner.

Arm type	Experimental
Investigational medicinal product name	V114
Investigational medicinal product code	
Other name	VAXNEUVANCE™ Pneumococcal 15-Valent Conjugate Vaccine
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

15-valent pneumococcal conjugate vaccine containing 15 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, 33F) given as a single 0.5 mL intramuscular injection at approximately 2, 4, 6, and 12 months of age on study Visit 1,2,3, and 4, respectively.

Investigational medicinal product name	INFANRIX™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Licensed pediatric vaccine for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type b given as a single 0.5 mL intramuscular injection at approximately 2, 4, and 6 months of age on study Visit 1, 2, and 3, respectively.

Investigational medicinal product name	RotaTeq™
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Oral suspension
Routes of administration	Oral use
Dosage and administration details:	
Licensed pediatric oral pentavalent vaccine for the prevention of rotavirus gastroenteritis given as a single 2 mL oral solution at approximately 2, 4, and 6 months of age on study Visit 1, 2, and 3, respectively.	
Investigational medicinal product name	Pentavac™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Licensed pediatric vaccine for the prevention of diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b given as a single 0.5 mL intramuscular injection at approximately 18 months of age on study Visit 5.	
Investigational medicinal product name	M-M-R™II
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Licensed pediatric vaccine for the prevention of measles, mumps, and rubella given as a single 0.5 mL subcutaneous injection at approximately 12 months of age on study Visit 4.	
Investigational medicinal product name	VARIVAX™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Licensed pediatric vaccine for the prevention of varicella given as a single 0.5 mL subcutaneous injection at approximately 12 and 18 months of age on study Visit 4 and 5, respectively.	
Investigational medicinal product name	VAQTA™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Licensed pediatric vaccine for the prevention of disease caused by hepatitis A virus given as a single 0.5 mL intramuscular injection at approximately 18 and 36 months of age on study Visit 5 and 6, respectively.	
Arm title	Control Group
Arm description:	
Participants received routine licensed pediatric vaccines, as follows: On Visits 1,2, and 3, at approximately 2, 4, and 6 months of age respectively participants received RECOMBIVAX HB™, Pentavac™, and RotaTeq™. On Visit 4 (~12 months of age) participants received VAQTA™ (Dose 1), M-M-R™II, and VARIVAX™ (Dose 1). On Visit 5 (~18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit and no study vaccines will be administered. For these participants, licensed Prevenar 13™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and Prevenar 13™ was administered in a blinded manner.	
Arm type	Active comparator

Investigational medicinal product name	Pentavac™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Licensed pediatric vaccine for the prevention of diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b given as a single 0.5 mL intramuscular injection at approximately 2, 4, 6, and 18 months of age on study Visit 1,2,3, and 5, respectively.

Investigational medicinal product name	RotaTeq™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:

Licensed pediatric oral pentavalent vaccine for the prevention of rotavirus gastroenteritis given as a single 2 mL oral solution at approximately 2, 4, and 6 months of age on study Visit 1, 2, and 3, respectively.

Investigational medicinal product name	Prevenar 13™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Licensed pediatric Pneumococcal 13-valent Conjugate Vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) for the prevention of pneumococcal disease caused by the serotypes contained in the vaccine given as a single 0.5 mL intramuscular injection at approximately 36 months of age on study Visit 6.

Investigational medicinal product name	M-M-R™II
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Licensed pediatric vaccine for the prevention of measles, mumps, and rubella given as a single 0.5 mL subcutaneous injection at approximately 12 months of age on study Visit 4.

Investigational medicinal product name	VARIVAX™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Licensed pediatric vaccine for the prevention of varicella given as a single 0.5 mL subcutaneous injection at approximately 12 and 18 months of age on study Visit 4 and 5, respectively.

Investigational medicinal product name	RECOMBIVAX HB™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Licensed pediatric vaccine for the prevention of hepatitis B virus infection given as a single 0.5 mL intramuscular injection at approximately 2, 4, and 6 months of age on study Visit 1,2, and 3, respectively.

Investigational medicinal product name	VAQTA™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Licensed pediatric vaccine for the prevention of disease caused by hepatitis A virus given as a single 0.5 mL intramuscular injection at approximately 12 and 18 months of age on study Visit 4 and 5, respectively.

Number of subjects in period 1	V114 Group	Control Group
Started	3560	3559
Primary Efficacy Analysis Population	2901 ^[1]	2925 ^[2]
Safety Analysis Population	3557	3556
Completed	3278	3292
Not completed	282	267
Physician decision	10	17
Death	4	2
Withdrawal by Parent/Guardian	205	186
Lost to follow-up	63	62

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The efficacy analysis population is based on the Per-Protocol (PP) population which consisted of all randomized participants who: received all injectable study vaccinations at 2, 4, and 6 months of age, had at least 1 follow-up visit/phone call for assessment of Vaccine Type-Acute Otitis Media (VT-AOM) ≥14 days after the injectable study vaccinations at 6 months of age; and, did not have any protocol deviations that may substantially affect the results of the efficacy endpoint.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Per protocol, the safety analyses population was the All Participants as Treated (APaT) which consisted of all randomized participants who received at least one study vaccination. Participants were included in the treatment group corresponding to the study treatment they actually received. Per the statistical analysis plan, participants who received both V114 and control vaccine were excluded from the safety analysis APaT population.

Baseline characteristics

Reporting groups

Reporting group title	V114 Group
Reporting group description:	
Participants received a single 0.5 mL intramuscular (IM) injection of V114 administered as a 4dose series on Visits 1,2,3, and 4, at approximately 2,4, 6, and 12 months of age respectively. V114 was administered concomitantly with routine licensed pediatric vaccines: INFANRIX™ hexa and RotaTeq™ on Visits 1, 2, and 3; and M M R™ II and VARIVAX™ (Dose 1) on Visit 4. On Visit 5 (approximately 18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit which and no study vaccines will be administered. For these participants, licensed VAQTA™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and VAQTA™ (Dose 2) was administered in a blinded manner.	
Reporting group title	Control Group
Reporting group description:	
Participants received routine licensed pediatric vaccines, as follows: On Visits 1,2, and 3, at approximately 2, 4, and 6 months of age respectively participants received RECOMBIVAX HB™, Pentavac™, and RotaTeq™. On Visit 4 (~12 months of age) participants received VAQTA™ (Dose 1), M-MR™II, and VARIVAX™ (Dose 1). On Visit 5 (~18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit and no study vaccines will be administered. For these participants, licensed Prevenar 13™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and Prevenar 13™ was administered in a blinded manner.	

Reporting group values	V114 Group	Control Group	Total
Number of subjects	3560	3559	7119
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	3560	3559	7119
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous			
Units: weeks			
arithmetic mean	8.6	8.6	
standard deviation	± 1.5	± 1.5	-
Gender Categorical			
Units: Participants			
Female	1723	1726	3449
Male	1837	1833	3670
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0

Asian	3558	3557	7115
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	2	2	4
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	3560	3559	7119
Unknown or Not Reported	0	0	0

End points

End points reporting groups

Reporting group title	V114 Group
Reporting group description:	
Participants received a single 0.5 mL intramuscular (IM) injection of V114 administered as a 4dose series on Visits 1,2,3, and 4, at approximately 2,4, 6, and 12 months of age respectively. V114 was administered concomitantly with routine licensed pediatric vaccines: INFANRIX™ hexa and RotaTeq™ on Visits 1, 2, and 3; and M M R™ II and VARIVAX™ (Dose 1) on Visit 4. On Visit 5 (approximately 18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit which and no study vaccines will be administered. For these participants, licensed VAQTA™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and VAQTA™ (Dose 2) was administered in a blinded manner.	
Reporting group title	Control Group
Reporting group description:	
Participants received routine licensed pediatric vaccines, as follows: On Visits 1,2, and 3, at approximately 2, 4, and 6 months of age respectively participants received RECOMBIVAX HB™, Pentavac™, and RotaTeq™. On Visit 4 (~12 months of age) participants received VAQTA™ (Dose 1), M-MR™II, and VARIVAX™ (Dose 1). On Visit 5 (~18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit and no study vaccines will be administered. For these participants, licensed Prevenar 13™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and Prevenar 13™ was administered in a blinded manner.	

Primary: Number of Participants with a First Episode of Vaccine-Type Acute Otitis Media (VT-AOM) Caused by the Pneumococcal Serotypes Contained in V114

End point title	Number of Participants with a First Episode of Vaccine-Type Acute Otitis Media (VT-AOM) Caused by the Pneumococcal Serotypes Contained in V114
End point description:	
The number of participants with a first episode of VT-AOM caused by the pneumococcal stereotypes contained in the V114 is presented. Per protocol, cases were defined as the first episode of VT-AOM diagnosed ≥14 days after the participant received study vaccinations at approximately 6 months of age (following Visit 3). Per protocol, the final analysis was conducted after at least 120 cases were accrued. Per protocol, the primary efficacy analysis population (Per-Protocol population) consisted of all randomized participants who: received all injectable study vaccinations at 2, 4, and 6 months of age; had at least 1 follow-up visit/phone call for assessment of VT-AOM ≥14 days after the injectable study vaccinations at 6 months of age; excluded perforated middle ear fluid samples; and did not have any protocol deviations that may substantially affect the results of the endpoint.	
End point type	Primary
End point timeframe:	
Up to approximately 30 months after Visit 3	

End point values	V114 Group	Control Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2901 ^[1]	2925 ^[2]		
Units: Participants	47	84		

Notes:

[1] - Subjects analyzed reflect the V114 Per Protocol (PP) population

[2] - Subjects analyzed reflect the Control Per Protocol (PP) population

Statistical analyses

Statistical analysis title	Observed Efficacy (%) of V114 versus Control
Statistical analysis description:	
Primary efficacy hypothesis used a two-sided multiplicity-adjusted exact 95% CI for vaccine efficacy based on the group-sequential methodology of Jennison & Turnbull (2000). The statistical criterion for success requires the lower bound of multiplicity-adjusted 95% CI of the vaccine efficacy to be >20%. Per protocol, cases are defined as first episode of VT-AOM diagnosed ≥ 14 days after the participant receives injectable study vaccinations at approximately 6 months of age (following Visit 3).	
Comparison groups	V114 Group v Control Group
Number of subjects included in analysis	5826
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Observed Efficacy (%)
Point estimate	43.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.87
upper limit	62.26

Primary: Number of Participants with Serious Adverse Events (SAEs)

End point title	Number of Participants with Serious Adverse Events (SAEs)
End point description:	
A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Per protocol, the safety analyses APaT population consisted of all randomized participants who had ≥ 1 study vaccination. Participants were included in the treatment group corresponding to the study treatment they actually received. Per the statistical analysis plan, participants who received both V114 and control vaccine were excluded from the safety analysis APaT population. The number of participants who experienced at least one SAE is reported. Per protocol, reported serious adverse events occurred from approximately 2 months of age (following Visit 1) through the completion of study participation.	
End point type	Primary
End point timeframe:	
Up to approximately 34 months	

End point values	V114 Group	Control Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3557 ^[3]	3556 ^[4]		
Units: Participants	963	1011		

Notes:

[3] - Subjects analyzed reflect the V114 All Participants as Treated (APaT) population

[4] - Subjects analyzed reflect the Control All Participants as Treated (APaT) population

Statistical analyses

Statistical analysis title	Difference in percent: V114 minus Control
Statistical analysis description:	
Estimated differences and confidence intervals (CIs) are calculated based on the Miettinen & Nurminen method.	
Comparison groups	V114 Group v Control Group
Number of subjects included in analysis	7113
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in % versus Control
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	0.7

Primary: Number of Participants with Vaccine-Related Serious Adverse Events (SAEs)

End point title	Number of Participants with Vaccine-Related Serious Adverse Events (SAEs)
End point description:	
A SAE is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed by medical or scientific judgment. A SAE defined by the investigator to be related to the study vaccine is considered vaccine-related. Per protocol, the safety analyses APaT population consisted of all randomized participants who had ≥ 1 study vaccination. Participants were included in the treatment group corresponding to the study treatment they actually received. Per the statistical analysis plan, participants who received both V114 and control vaccine were excluded from the safety analysis APaT population. The number of participants who experienced at ≥ 1 vaccine-related SAE is reported. Per protocol, reported SAEs occurred from approximately 2 months of age (following Visit 1) through the completion of study participation.	
End point type	Primary
End point timeframe:	
Up to approximately 34 months	

End point values	V114 Group	Control Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3557 ^[5]	3556 ^[6]		
Units: Participants	3	2		

Notes:

[5] - Subjects analyzed reflect the V114 All Participants as Treated (APaT) population

[6] - Subjects analyzed reflect the Control All Participants as Treated (APaT) population

Statistical analyses

Statistical analysis title	Difference in percent: V114 minus Control
Statistical analysis description:	
Estimated differences and CIs are calculated based on the Miettinen & Nurminen method.	
Comparison groups	V114 Group v Control Group
Number of subjects included in analysis	7113
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in % versus Control
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.2

Primary: Number of Participants Who Discontinued the Study Vaccine Due to Serious Adverse Events (SAEs)

End point title	Number of Participants Who Discontinued the Study Vaccine Due to Serious Adverse Events (SAEs)
End point description:	
A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Per protocol, the safety analyses APaT population consisted of all randomized participants who had ≥ 1 study vaccination. Participants were included in the treatment group corresponding to the study treatment they actually received. Per the statistical analysis plan, participants who received both V114 and control vaccine were excluded from the safety analysis APaT population. The number of participants who discontinued the study vaccine due to an SAE is reported. Per protocol, reported serious adverse events occurred from approximately 2 months of age (following Visit 1) through the completion of study participation.	
End point type	Primary
End point timeframe:	
Up to approximately 34 months	

End point values	V114 Group	Control Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3557 ^[7]	3556 ^[8]		
Units: Participants	2	1		

Notes:

[7] - Subjects analyzed reflect the V114 All Participants as Treated (APaT) population

[8] - Subjects analyzed reflect the Control All Participants as Treated (APaT) population

Statistical analyses

Statistical analysis title	Difference in percent: V114 minus Control
Statistical analysis description:	
Estimated differences and CIs are calculated based on the Miettinen & Nurminen method.	
Comparison groups	Control Group v V114 Group
Number of subjects included in analysis	7113
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in % versus Control
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.2

Primary: Number of Participants Who Died

End point title	Number of Participants Who Died
End point description:	
The number of participants who died from any cause during the study is presented. Per protocol, the safety analyses APaT population consisted of all randomized participants who had ≥ 1 study vaccination. Participants were included in the treatment group corresponding to the study treatment they actually received. Per the statistical analysis plan, participants who received both V114 and control vaccine were excluded from the safety analysis APaT population. The number of participants who died from any cause during the study is reported. Per protocol, reported serious adverse events occurred from approximately 2 months of age (following Visit 1) through the completion of study participation.	
End point type	Primary
End point timeframe:	
Up to approximately 34 months	

End point values	V114 Group	Control Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3557 ^[9]	3556 ^[10]		
Units: Participants	4	2		

Notes:

[9] - Subjects analyzed reflect the V114 All Participants as Treated (APaT) population

[10] - Subjects analyzed reflect the Control All Participants as Treated (APaT) population

Statistical analyses

Statistical analysis title	Difference in percent: V114 minus Control
Statistical analysis description:	
Estimated differences and CIs are calculated based on the Miettinen & Nurminen method.	
Comparison groups	V114 Group v Control Group
Number of subjects included in analysis	7113
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in % versus Control
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.2

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

up to approximately 34 months

Adverse event reporting additional description:

All-Cause Mortality: all randomized participants SAEs: all randomized participants who had ≥ 1 study vaccination included in treatment group corresponding to treatment received. Per protocol, Non-Serious AEs not collected. Per statistical analysis plan, participants who had both V114 & Control vaccine were excluded from safety analysis population.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	28.1
--------------------	------

Reporting groups

Reporting group title	Control Group
-----------------------	---------------

Reporting group description:

Participants received routine licensed pediatric vaccines, as follows: On Visits 1,2, and 3, at approximately 2, 4, and 6 months of age respectively participants received RECOMBIVAX HB™, Pentavac™, and RotaTeq™. On Visit 4 (~12 months of age) participants received VAQTA™ (Dose 1), M-MR™II, and VARIVAX™ (Dose 1). On Visit 5 (~18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit and no study vaccines will be administered. For these participants, licensed Prevenar 13™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and Prevenar 13™ was administered in a blinded manner.

Reporting group title	V114 Group
-----------------------	------------

Reporting group description:

Participants received a single 0.5 mL intramuscular (IM) injection of V114 administered as a 4dose series on Visits 1,2,3, and 4, at approximately 2,4, 6, and 12 months of age respectively. V114 was administered concomitantly with routine licensed pediatric vaccines: INFANRIX™ hexa and RotaTeq™ on Visits 1, 2, and 3; and M M R™ II and VARIVAX™ (Dose 1) on Visit 4. On Visit 5 (approximately 18 months of age), participants received unblinded VAQTA™ (Dose 1), VARIVAX™ (Dose 2), and Pentavac™. For participants 19 to 35 months of age who have completed Visit 5 by the time the efficacy or futility criterion is met, Visit 6 will be a safety follow-up visit which and no study vaccines will be administered. For these participants, licensed VAQTA™ may be offered outside of the study. For participants who reached Visit 6 (approximately 36 months of age) before the efficacy or futility criterion was met, Visit 6 was the final study visit and VAQTA™ (Dose 2) was administered in a blinded manner.

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Per protocol, Non-Serious Adverse Events were not collected.

Serious adverse events	Control Group	V114 Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	1011 / 3556 (28.43%)	963 / 3557 (27.07%)	
number of deaths (all causes)	2	4	
number of deaths resulting from adverse events	2	4	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma			

subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoblastoma			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypovolaemic shock			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kawasaki's disease			
subjects affected / exposed	7 / 3556 (0.20%)	5 / 3557 (0.14%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphangiectasia			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Drowning			
subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Influenza like illness			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	15 / 3556 (0.42%)	18 / 3557 (0.51%)	
occurrences causally related to treatment / all	1 / 15	2 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	

Sudden infant death syndrome			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Polyp			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Allergy to arthropod bite			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	2 / 3556 (0.06%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food allergy			
subjects affected / exposed	4 / 3556 (0.11%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Milk allergy			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multisystem inflammatory syndrome in children			
subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	18 / 3556 (0.51%)	15 / 3557 (0.42%)	
occurrences causally related to treatment / all	0 / 22	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brief resolved unexplained event			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial hyperreactivity			
subjects affected / exposed	2 / 3556 (0.06%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal hypertrophy			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rebound nasal congestion			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Upper airway obstruction subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wheezing subjects affected / exposed	10 / 3556 (0.28%)	8 / 3557 (0.22%)	
occurrences causally related to treatment / all	0 / 12	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders Phagophobia subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breath holding subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations Influenza A virus test positive subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SARS-CoV-2 test positive subjects affected / exposed	21 / 3556 (0.59%)	24 / 3557 (0.67%)	
occurrences causally related to treatment / all	0 / 21	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications Accidental exposure to product subjects affected / exposed	2 / 3556 (0.06%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Animal bite			

subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			
subjects affected / exposed	1 / 3556 (0.03%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exposure to communicable disease			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immunisation reaction			

subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body ingestion			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in gastrointestinal tract			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body aspiration			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	0 / 3556 (0.00%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			

subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord injury			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Snake bite			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Buried penis syndrome			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital absence of bile ducts			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital intestinal obstruction			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital megacolon			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular septal defect			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid ptosis congenital			

subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phimosis			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cryptorchism			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Nervous system disorders			
Syncope			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 3556 (0.00%)	6 / 3557 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lennox-Gastaut syndrome			

subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infantile spasms			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile convulsion			
subjects affected / exposed	61 / 3556 (1.72%)	67 / 3557 (1.88%)	
occurrences causally related to treatment / all	0 / 71	0 / 84	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	3 / 3556 (0.08%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign enlargement of the subarachnoid spaces			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Eosinophilia			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenia			
subjects affected / exposed	2 / 3556 (0.06%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	1 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			

subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis			
subjects affected / exposed	3 / 3556 (0.08%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Chalazion			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strabismus			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryostenosis acquired			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	13 / 3556 (0.37%)	9 / 3557 (0.25%)	
occurrences causally related to treatment / all	0 / 15	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			

subjects affected / exposed	4 / 3556 (0.11%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eosinophilic colitis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	6 / 3556 (0.17%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	12 / 3556 (0.34%)	15 / 3557 (0.42%)	
occurrences causally related to treatment / all	0 / 13	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileal perforation			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intussusception			
subjects affected / exposed	4 / 3556 (0.11%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary tract disorder			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis allergic			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema multiforme			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	4 / 3556 (0.11%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			

Renal artery stenosis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Fistula			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal mass			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigger finger			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Adenovirus infection			
subjects affected / exposed	1 / 3556 (0.03%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Adenoviral conjunctivitis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amoebiasis			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	8 / 3556 (0.22%)	9 / 3557 (0.25%)	
occurrences causally related to treatment / all	0 / 9	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	3 / 3556 (0.08%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial diarrhoea			

subjects affected / exposed	3 / 3556 (0.08%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial rhinitis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	64 / 3556 (1.80%)	49 / 3557 (1.38%)	
occurrences causally related to treatment / all	0 / 73	0 / 55	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	34 / 3556 (0.96%)	32 / 3557 (0.90%)	
occurrences causally related to treatment / all	0 / 36	0 / 33	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis mycoplasmal			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amoebic dysentery			

subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burn infection			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis viral			
subjects affected / exposed	4 / 3556 (0.11%)	7 / 3557 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	60 / 3556 (1.69%)	44 / 3557 (1.24%)	
occurrences causally related to treatment / all	0 / 60	0 / 44	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	3 / 3556 (0.08%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis staphylococcal			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conjunctivitis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Croup infectious			
subjects affected / exposed	20 / 3556 (0.56%)	16 / 3557 (0.45%)	
occurrences causally related to treatment / all	0 / 21	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			

subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	9 / 3556 (0.25%)	6 / 3557 (0.17%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue haemorrhagic fever			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	17 / 3556 (0.48%)	13 / 3557 (0.37%)	
occurrences causally related to treatment / all	0 / 17	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epstein-Barr virus infection			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia pyelonephritis			
subjects affected / exposed	4 / 3556 (0.11%)	5 / 3557 (0.14%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	15 / 3556 (0.42%)	15 / 3557 (0.42%)	
occurrences causally related to treatment / all	0 / 15	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exanthema subitum			

subjects affected / exposed	32 / 3556 (0.90%)	32 / 3557 (0.90%)	
occurrences causally related to treatment / all	0 / 32	0 / 32	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	173 / 3556 (4.87%)	191 / 3557 (5.37%)	
occurrences causally related to treatment / all	0 / 174	0 / 192	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis Escherichia coli			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis adenovirus			
subjects affected / exposed	2 / 3556 (0.06%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	2 / 3556 (0.06%)	7 / 3557 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis enteroviral			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	5 / 3556 (0.14%)	7 / 3557 (0.20%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis rotavirus			
subjects affected / exposed	2 / 3556 (0.06%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			

subjects affected / exposed	13 / 3556 (0.37%)	12 / 3557 (0.34%)	
occurrences causally related to treatment / all	0 / 13	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis shigella			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	48 / 3556 (1.35%)	32 / 3557 (0.90%)	
occurrences causally related to treatment / all	0 / 49	0 / 32	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal bacterial infection			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal viral infection			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingivitis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HCoV-OC43 infection			
subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand-foot-and-mouth disease			
subjects affected / exposed	21 / 3556 (0.59%)	24 / 3557 (0.67%)	
occurrences causally related to treatment / all	0 / 21	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpangina			

subjects affected / exposed	12 / 3556 (0.34%)	16 / 3557 (0.45%)
occurrences causally related to treatment / all	0 / 12	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 0
Hordeolum		
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis		
subjects affected / exposed	123 / 3556 (3.46%)	113 / 3557 (3.18%)
occurrences causally related to treatment / all	0 / 133	0 / 121
deaths causally related to treatment / all	0 / 0	0 / 0
Human bocavirus infection		
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Mycoplasma infection		
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Infected cyst		
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Infectious mononucleosis		
subjects affected / exposed	2 / 3556 (0.06%)	2 / 3557 (0.06%)
occurrences causally related to treatment / all	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Influenza		
subjects affected / exposed	30 / 3556 (0.84%)	26 / 3557 (0.73%)
occurrences causally related to treatment / all	0 / 30	0 / 27
deaths causally related to treatment / all	0 / 0	0 / 0
Klebsiella urinary tract infection		

subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis viral			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ludwig angina			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymph node tuberculosis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis bacterial			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Measles			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis pneumococcal			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metapneumovirus bronchiolitis			

subjects affected / exposed	3 / 3556 (0.08%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metapneumovirus infection			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metapneumovirus pneumonia			
subjects affected / exposed	4 / 3556 (0.11%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impetigo			
subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	19 / 3556 (0.53%)	19 / 3557 (0.53%)	
occurrences causally related to treatment / all	0 / 19	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia adenoviral			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral herpes			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			

subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media acute			
subjects affected / exposed	20 / 3556 (0.56%)	15 / 3557 (0.42%)	
occurrences causally related to treatment / all	0 / 21	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae viral bronchitis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	0 / 3556 (0.00%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotitis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital cellulitis			
subjects affected / exposed	3 / 3556 (0.08%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	19 / 3556 (0.53%)	8 / 3557 (0.22%)	
occurrences causally related to treatment / all	0 / 19	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis bacterial			

subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngotonsillitis			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal sepsis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	75 / 3556 (2.11%)	71 / 3557 (2.00%)	
occurrences causally related to treatment / all	0 / 81	0 / 79	
deaths causally related to treatment / all	0 / 0	0 / 0	
Norovirus infection			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinovirus infection			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia chlamydial			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia influenzal			

subjects affected / exposed	4 / 3556 (0.11%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	3 / 3556 (0.08%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia parainfluenzae viral			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia respiratory syncytial viral			
subjects affected / exposed	46 / 3556 (1.29%)	53 / 3557 (1.49%)	
occurrences causally related to treatment / all	0 / 47	0 / 54	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia viral			
subjects affected / exposed	82 / 3556 (2.31%)	62 / 3557 (1.74%)	
occurrences causally related to treatment / all	0 / 93	0 / 75	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	5 / 3556 (0.14%)	8 / 3557 (0.22%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyomyositis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyuria			

subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	17 / 3556 (0.48%)	28 / 3557 (0.79%)	
occurrences causally related to treatment / all	0 / 17	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchitis			
subjects affected / exposed	12 / 3556 (0.34%)	18 / 3557 (0.51%)	
occurrences causally related to treatment / all	0 / 12	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	21 / 3556 (0.59%)	11 / 3557 (0.31%)	
occurrences causally related to treatment / all	0 / 21	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinitis			
subjects affected / exposed	2 / 3556 (0.06%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	28 / 3556 (0.79%)	27 / 3557 (0.76%)	
occurrences causally related to treatment / all	0 / 30	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic viral infection			
subjects affected / exposed	0 / 3556 (0.00%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotavirus infection			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonella bacteraemia			

subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonella sepsis			
subjects affected / exposed	3 / 3556 (0.08%)	4 / 3557 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonellosis			
subjects affected / exposed	3 / 3556 (0.08%)	8 / 3557 (0.22%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scabies			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal sepsis			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrub typhus			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	0 / 3556 (0.00%)	3 / 3557 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin bacterial infection			

subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal abscess			
subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scarlet fever			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	6 / 3556 (0.17%)	5 / 3557 (0.14%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis bacterial			
subjects affected / exposed	1 / 3556 (0.03%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth infection			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicella			

subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	18 / 3556 (0.51%)	7 / 3557 (0.20%)	
occurrences causally related to treatment / all	0 / 18	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection bacterial			
subjects affected / exposed	2 / 3556 (0.06%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	9 / 3556 (0.25%)	14 / 3557 (0.39%)	
occurrences causally related to treatment / all	0 / 9	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis viral			
subjects affected / exposed	0 / 3556 (0.00%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral diarrhoea			
subjects affected / exposed	1 / 3556 (0.03%)	2 / 3557 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	21 / 3556 (0.59%)	19 / 3557 (0.53%)	
occurrences causally related to treatment / all	0 / 21	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral pharyngitis			

subjects affected / exposed	1 / 3556 (0.03%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral rash			
subjects affected / exposed	10 / 3556 (0.28%)	9 / 3557 (0.25%)	
occurrences causally related to treatment / all	0 / 10	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral tonsillitis			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	10 / 3556 (0.28%)	9 / 3557 (0.25%)	
occurrences causally related to treatment / all	0 / 10	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophagia			
subjects affected / exposed	1 / 3556 (0.03%)	0 / 3557 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			

subjects affected / exposed	0 / 3556 (0.00%)	1 / 3557 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Control Group	V114 Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 3556 (0.00%)	0 / 3557 (0.00%)	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 June 2021	Amendment 01: The rationale for this amendment is to incorporate changes to the statistical criteria for success of the primary hypothesis to allow for a more stringent assessment of vaccine efficacy.
01 July 2021	Amendment 02: The rationale for this amendment is to allow flexibility in the sourcing of licensed pediatric vaccines.
06 January 2023	Amendment 03: The rationale for this amendment is to increase the study sample size to mitigate for challenges posed by the COVID-19 pandemic on VT-AOM case accrual.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported